
TY  - JOUR
AU  - Tobyne, Sean M.
AU  - Boratyn, Daria
AU  - Johnson, Jessica A.
AU  - Greve, Douglas N.
AU  - Mainero, Caterina
AU  - Klawiter, Eric C.
TI  - A surface-based technique for mapping homotopic interhemispheric connectivity: Development, characterization, and clinical application
JO  - Human Brain Mapping
JA  - Hum. Brain Mapp.
VL  - 37
IS  - 8
SN  - 1065-9471
UR  - https://doi.org/10.1002/hbm.23214
DO  - doi:10.1002/hbm.23214
SP  - 2849
EP  - 2868
KW  - functional connectivity
KW  - resting state
KW  - multiple sclerosis
KW  - corpus callosum
KW  - human
PY  - 2016
AB  - Abstract The functional organization of the human brain consists of a high degree of connectivity between interhemispheric homologous regions. The degree of homotopic organization is known to vary across the cortex and homotopic connectivity is high in regions that share cross-hemisphere structural connections or are activated by common input streams (e.g., the visual system). Damage to one or both regions, as well as damage to the connections between homotopic regions, could disrupt this functional organization. Here were introduce and test a computationally efficient technique, surface-based homotopic interhermispheric connectivity (sHIC), that leverages surface-based registration and processing techniques in an attempt to improve the spatial specificity and accuracy of cortical interhemispheric connectivity estimated with resting state functional connectivity. This technique is shown to be reliable both within and across subjects. sHIC is also characterized in a dataset of nearly 1000 subjects. We confirm previous results showing increased interhemispheric connectivity in primary sensory regions, and reveal a novel rostro-caudal functionally defined network level pattern of sHIC across the brain. In addition, we demonstrate a structural?functional relationship between sHIC and atrophy of the corpus callosum in multiple sclerosis (r?=?0.2979, p?=?0.0461). sHIC presents as a sensitive and reliable measure of cortical homotopy that may prove useful as a biomarker in neurologic disease. Hum Brain Mapp 37:2849?2868, 2016. ? 2016 Wiley Periodicals, Inc.
ER  - 

TY  - JOUR
TI  - Specialised Systems Pharmacology
JO  - Basic & Clinical Pharmacology & Toxicology
JA  - Basic Clin Pharmacol Toxicol
VL  - 115
IS  - s1
SN  - 1742-7835
UR  - https://doi.org/10.1111/bcpt.12259_14
DO  - doi:10.1111/bcpt.12259_14
SP  - 339
EP  - 349
PY  - 2014
ER  - 

TY  - JOUR
AU  - Mazibuko, Zamanzima
AU  - Choonara, Yahya E.
AU  - Kumar, Pradeep
AU  - Du Toit, Lisa C.
AU  - Modi, Girish
AU  - Naidoo, Dinesh
AU  - Pillay, Viness
TI  - A Review of the Potential Role of Nano-Enabled Drug Delivery Technologies in Amyotrophic Lateral Sclerosis: Lessons Learned from Other Neurodegenerative Disorders
JO  - Journal of Pharmaceutical Sciences
JA  - J. Pharm. Sci.
VL  - 104
IS  - 4
SN  - 0022-3549
UR  - https://doi.org/10.1002/jps.24322
DO  - doi:10.1002/jps.24322
SP  - 1213
EP  - 1229
KW  - amyotrophic lateral sclerosis
KW  - nanotechnology
KW  - drug delivery
KW  - neurotrophic factors
KW  - blood–brain barrier
KW  - clinical trials
KW  - neurodegenerative disorders
KW  - bioavailability
PY  - 2015
AB  - Amyotrophic lateral sclerosis (ALS) has a multitude of factors implicated in its etiology. The complex neuro-etiology and the restrictive nature of the blood?brain barrier (BBB) have significantly hindered the drug therapy of ALS. Riluzole, a moderately performing drug, is the only agent approved for treating ALS. However, several promising nanocarrier approaches are surfacing that can provide more efficient drug delivery. In addition, biologicals such as stem cells are able to carry neurotrophic factors to their target site, providing motor neurons with the benefits of both, stem cells and neurotrophic factors. This review examines the current drug delivery strategies investigated for optimally treating ALS and related neurodegenerative disorders. Examples include cerium oxide nanoparticles in Alzheimer's disease, odorranalectin, and lactoferrin-coupled PEG?PLGA nanoparticles for urocortin transportation in Parkinson's disease that can also be employed in ALS to bypass the BBB and increase drug bioavailability. A concise incursion into the progress (and lack thereof) made in ALS clinical trials is also discussed. Nanocarriers can potentially eliminate the challenges of poor drug bioavailability in ALS as they have been proven to cross the BBB and reach target sites while minimizing systemic side-effects. Nanocarrier-based delivery of ALS drugs is an area that requires much needed investigation. ? 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:1213?1229, 2015
ER  - 

TY  - JOUR
TI  - Abstracts and Index of Authors
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
JA  - Pharmacotherapy
VL  - 33
IS  - 10
SN  - 0277-0008
UR  - https://doi.org/10.1002/phar.1356
DO  - doi:10.1002/phar.1356
SP  - e182
EP  - e332
PY  - 2013
ER  - 

TY  - JOUR
AU  - Dodor, Bernice A.
AU  - Woods, Barbara A.
TI  - A Listing of Theses and Dissertations Completed in Family and Consumer Sciences: 2009
JO  - Family and Consumer Sciences Research Journal
VL  - 39
IS  - 2
SN  - 1077-727X
UR  - https://doi.org/10.1111/j.1552-3934.2010.02058.x
DO  - doi:10.1111/j.1552-3934.2010.02058.x
SP  - 200
EP  - 225
PY  - 2010
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - Transplant International
VL  - 20
IS  - s2
SN  - 0934-0874
UR  - https://doi.org/10.1111/j.1432-2277.2007.00577.x
DO  - doi:10.1111/j.1432-2277.2007.00577.x
SP  - 97
EP  - 329
PY  - 2007
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Diseases of the Esophagus
JA  - DISEASES OF THE ESOPHAGUS
VL  - 29
IS  - S1
SN  - 1120-8694
UR  - https://doi.org/10.1111/dote.12528
DO  - doi:10.1111/dote.12528
SP  - 3A
EP  - 162A
PY  - 2016
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of General Internal Medicine
VL  - 17
IS  - S1
SN  - 0884-8734
UR  - https://doi.org/10.1046/j.1525-1497.17.s1.9.x
DO  - doi:10.1046/j.1525-1497.17.s1.9.x
SP  - 27
EP  - 252
PY  - 2002
ER  - 

TY  - JOUR
TI  - Clinical Radiology Educational Exhibits
JO  - Journal of Medical Imaging and Radiation Oncology
JA  - J Med Imaging Radiat Oncol
VL  - 63
IS  - S1
SN  - 1754-9477
UR  - https://doi.org/10.1111/1754-9485.12956
DO  - doi:10.1111/1754-9485.12956
SP  - 105
EP  - 151
PY  - 2019
ER  - 

TY  - JOUR
C7  - e13671
TI  - Abstracts
JO  - Neurogastroenterology & Motility
JA  - Neurogastroenterology & Motility
VL  - 31
IS  - S4
SN  - 1350-1925
UR  - https://doi.org/10.1111/nmo.13671
DO  - doi:10.1111/nmo.13671
SP  - e13671
PY  - 2019
ER  - 

TY  - JOUR
TI  - AASLD Abstracts
JO  - Hepatology
JA  - Hepatology
VL  - 58
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.26727
DO  - doi:10.1002/hep.26727
SP  - 208A
EP  - 1309A
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts of ICI 2016 International Congress of Immunology, 21–26 August 2016, Melbourne, Australia
JO  - European Journal of Immunology
JA  - Eur. J. Immunol.
VL  - 46
IS  - S1
SN  - 0014-2980
UR  - https://doi.org/10.1002/eji.201670200
DO  - doi:10.1002/eji.201670200
SP  - 1
EP  - 1274
PY  - 2016
ER  - 

TY  - JOUR
TI  - Mini Oral Abstracts
JO  - Nephrology
JA  - Nephrology
VL  - 21
IS  - S2
SN  - 1320-5358
UR  - https://doi.org/10.1111/nep.12887
DO  - doi:10.1111/nep.12887
SP  - 58
EP  - 149
PY  - 2016
ER  - 

TY  - JOUR
AU  - Chapple, Iain L. C.
AU  - Matthews, John B.
TI  - The role of reactive oxygen and antioxidant species in periodontal tissue destruction
JO  - Periodontology 2000
VL  - 43
IS  - 1
SN  - 0906-6713
UR  - https://doi.org/10.1111/j.1600-0757.2006.00178.x
DO  - doi:10.1111/j.1600-0757.2006.00178.x
SP  - 160
EP  - 232
PY  - 2007
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Hepatology
JA  - Hepatology
VL  - 54
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.24666
DO  - doi:10.1002/hep.24666
SP  - 360A
EP  - 1455A
PY  - 2011
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Journal of Peptide Science
JA  - J. Peptide Sci.
VL  - 14
IS  - S1
SN  - 1075-2617
UR  - https://doi.org/10.1002/psc.1090
DO  - doi:10.1002/psc.1090
SP  - 47
EP  - 194
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Haemophilia
JA  - Haemophilia
VL  - 26
IS  - S2
SN  - 1351-8216
UR  - https://doi.org/10.1111/hae.13911
DO  - doi:10.1111/hae.13911
SP  - 27
EP  - 181
PY  - 2020
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Mycoses
VL  - 55
IS  - s4
SN  - 0933-7407
UR  - https://doi.org/10.1111/j.1439-0507.2012.02206.x
DO  - doi:10.1111/j.1439-0507.2012.02206.x
SP  - 95
EP  - 338
PY  - 2012
ER  - 

AU  - Bourke, Billy
AU  - Hussey, Séamus
C7  - pp. 1249-1263
TI  - Chronic Infections of the Small Intestine
SN  - 9781118512067
UR  - https://doi.org/10.1002/9781118512074.ch63
DO  - doi:10.1002/9781118512074.ch63
SP  - 1249-1263
KW  - mycotic infections
KW  - small intestine
KW  - small-bowel biopsy
KW  - tropical sprue
KW  - tuberculosis
KW  - Whipple's disease
PY  - 2012
AB  - Summary The advent of molecular genetic techniques and successful cell culture of the organism towards the end of the 20th century substantially accelerated the understanding of the causative organism, Tropheryma whipplei, and by extension, the underlying clinical condition. Whipple's disease usually is diagnosed at an advanced stage and presents with a variety of clinical manifestations. In classic Whipple's disease small-bowel biopsy usually establishes the diagnosis. The effectiveness of antimicrobials, especially poorly absorbed antibiotics, as the mainstay for treating tropical sprue establishes the central role of enteric bacteria/bacterial overgrowth in the condition. Mycotic infections usually arise from disseminated pulmonary infections and occur usually, but not exclusively, in immunocompromised patients. The differential diagnosis for all mycotic infections of the small intestine is similar and includes other mycotic infections, Crohn's disease, tuberculosis (TB) enteritis, disseminated mycobacterium avium complex (MAC), bacterial typhlitis, intestinal ischemia and carcinoma.
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - Nephrology
JA  - Nephrology
VL  - 19
IS  - S2
SN  - 9781118512067
UR  - https://doi.org/10.1111/nep.12237
DO  - doi:10.1111/nep.12237
SP  - 77
EP  - 202
PY  - 2014
ER  - 
